Net sales of $1.140 billion, increased 6.0% sequentially and declined 2.0% from the year ago quarter. The midpoint of our guidance provided on August 7, 2025 was net sales of $1.130 billion.On a GAAP basis: gross profit of 55.9%; operating income of $88.9 million and 7.8% of net sales; net income attributable to common stockholders of $13.9 million; and EPS of $0.03 per diluted share. Our guidance provided on August 7, 2025 was for GAAP EPS loss per diluted share of $0.04 to $0.01.On a Non-GAAP basis: gross ...

Management to Host Conference Call on Thursday, November 13, 2025, at 9:00 a.m. Eastern timeBALLERUP, Denmark, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a high-tech filtration company that manufactures and markets highly specialized filtration products and systems, will report third quarter 2025 financial results for the period ended September 30, 2025, on Thursday, November 13, 2025, before the market opens. The Company has scheduled a conference call that same day, Thur ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, ...

CINCINNATI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The E.W. Scripps Company (NASDAQ: SSP) delivered $526 million in revenue for the third quarter of 2025. Loss attributable to the shareholders of Scripps was $49 million or 55 cents per share. Business notes: Local Media division core advertising revenue was up 2% in the third quarter, driven by the services category and overall growth in national advertising due to strong sales execution and Scripps’ sports strategy. During the fourth quarter, the company expect ...

Dallas, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- November 6, 2025…Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $37.0 million, or $.32 per share, in the third quarter of 2025 compared to net income of $71.8 million, or $.62 per share, in the third quarter of 2024. For the first nine months of 2025, Kronos Worldwide reported a net loss of $28.1 million, or $.24 per share, compared to net income of $99.4 million, or $.86 per share, in the first nine months of 2024. Net loss increased in the t ...

TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its Common Shares on November 6, 2025. The Company is not aware of any material developments in its business or affairs beyond those that have been publicly disclosed. Investors should rely solely on the Company’s filings with the SEC and its press releases. The Company is issuing this press release p ...

eXp World Holdings Reports Q3 2025 Results eXp World Holdings Reports Q3 2025 Results BELLINGHAM, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced financial results for the third quarter ended September 30, 2025. “Our third quarter results underscore the strength of eXp’s model and the power of our agents,” said Leo Pareja, CEO of eXp Realty. “Continued momentum in ...

Increased Net Sales 9.4% in Quarter, 8.7% in Fiscal Year Earned Net Income per Diluted Share of $0.33 in Quarter, $1.22 in Fiscal Year Reported Adjusted Net Income per Diluted Share of $0.38 in Quarter, $1.31 in Fiscal Year Generated Adjusted EBITDA of $91.8 million in Quarter, $326.2 million in Fiscal Year ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mueller Water Products, Inc. (NYSE: MWA), a leading manufacturer and marketer of products and solutions used in the transmission, distribution and measurement o ...

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided a ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended September 30, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedQuarter EndedQuarter EndedSeptember 30, 2025June 30, 2025September 30, 2024 Net Investment Income (“NII”)$79,350$79,043<td style="border-right: solid black 1pt ; border-bottom: solid blac ...